SCHEMBL1962748

SCHEMBL1962748

CCCCCCCCCCC(CCCCCCCC)COS(C)(=O)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 10/20 0.47
CA2 P00918 10/20 0.47
CA12 O43570 4/20 0.47
CA7 P43166 4/20 0.47
CA14 Q9ULX7 4/20 0.47
LMNA P02545 2/20 0.43
CA9 Q16790 8/20 0.39
CA3 P07451 2/20 0.39
CA4 P22748 2/20 0.39
CA6 P23280 2/20 0.39
CA5A P35218 2/20 0.39
CA5B Q9Y2D0 2/20 0.39
RECQL P46063 2/20 0.38
TSHR P16473 2/20 0.38
GLA P06280 1/20 0.38
HPGD P15428 1/20 0.38
MAPK1 P28482 1/20 0.38
EPHX2 P34913 1/20 0.38
TP53 P04637 1/20 0.38
BLM P54132 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31272586 1.00 CA1 (0.47) CA1CA2CA12CA7CA14
SCHEMBL12955914 1.00 CA1 (0.47) CA1CA2CA12CA7CA14
SCHEMBL8982625 1.00 CA1 (0.47) CA1CA2CA12CA7CA14
SCHEMBL16415818 0.98 CA2 (0.46) CA1CA2CA12CA7CA14
SCHEMBL9566890 0.93 LMNA (0.42) CA1CA2CA12CA7CA14
SCHEMBL16759507 0.92 CYP3A4 (0.46) CA1CA2CA12CA7CA14
SCHEMBL28069731 0.92 CYP3A4 (0.46) CA1CA2CA12CA7CA14
SCHEMBL28272444 0.92 CYP3A4 (0.46) CA1CA2CA12CA7CA14
SCHEMBL28142509 0.90 CYP3A4 (0.47) CA1CA2CA12CA7CA14
SCHEMBL1710998 0.88 CA2 (0.57) CA1CA2CA12CA7CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206206-B2 Oxidized lipid compounds and uses thereof VASCULAR BIOGENICS LTD. (IL) 2015-12-08 US disclosed
EP-2826369-A2 Oxidized lipid compounds and uses thereof Vascular Biogenics Ltd. (IL) 2015-01-21 EP disclosed
EP-2826370-A2 Oxidized lipid compounds and uses thereof Vascular Biogenics Ltd. (IL) 2015-01-21 EP disclosed
EP-2348866-B1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF VASCULAR BIOGENICS LTD (IL) 2015-01-07 EP disclosed
US-20130203707-A1 Oxidized Lipid Compounds and Uses Thereof VASCULAR BIOGENICS LTD. (IL) 2013-08-08 US disclosed
US-20110207703-A1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF VASCULAR BIOGENICS LTD. (IL) 2011-08-25 US disclosed
EP-2348866-A1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF Vascular Biogenics Ltd. (IL) 2011-08-03 EP disclosed
WO-2010052718-A9 OXIDIZED LIPID COMPOUNDS AND USES THEREOF VASCULAR BIOGENICS LTD. (IL) 2011-06-16 WO disclosed
WO-2010052718-A1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF VASCULAR BIOGENICS LTD. (IL) 2010-05-14 WO disclosed
EP-0423764-B1 Silver halide colour photographic material and cyan coupler of the 2-phenylureido-5-acylaminophenol type FUJI PHOTO FILM CO LTD (JP) 1996-05-08 EP disclosed
US-5094938-A High coupling reactivity, high color density FUJI PHOTO FILM CO., LTD. (JP) 1992-03-10 US disclosed
EP-0423764-A2 Silver halide colour photographic material and cyan coupler of the 2-phenylureido-5-acylaminophenol type FUJI PHOTO FILM CO., LTD. (JP) 1991-04-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203707-A1 Oxidized Lipid Compounds and Uses Thereof LPO, GPX4, ALOX15B CA1 3989/4885CA2 3456/4885CA12 3239/4885
US-20110207703-A1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF LPO, GPX4, ALOX15B CA1 3989/4885CA2 3456/4885CA12 3239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.